Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
next-generation neoantigen-selected tumor-infiltrating lymphocytes
- Development stage
- Unknown
- Lead developer
- Vall d'Hebron Institute of Oncology
- Modality
- Cell Therapies
- Administration
- Intravenous
01
Overview
Next-generation neoantigen-selected tumor-infiltrating lymphocytes (TILs) is an autologous adoptive cell therapy developed by the Vall d'Hebron Institute of Oncology (VHIO). This therapeutic approach involves the isolation of T cells from a patient's tumor, followed by a selection process to identify and enrich for T cells that specifically recognize patient-specific neoantigens—mutations unique to the individual's cancer. These selected T cells are expanded ex vivo to therapeutic quantities and re-infused into the patient after a lymphodepleting conditioning regimen. The goal of this "next-generation" selection process is to improve the efficacy of TIL therapy by ensuring the infused product is highly enriched for tumor-reactive cells, potentially overcoming the limitations of unselected TIL products in epithelial and immune checkpoint blockade-resistant solid tumors.
- Other names
- neoantigen-selected TILsnext-generation TILs
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on next-generation neoantigen-selected tumor-infiltrating lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on next-generation neoantigen-selected tumor-infiltrating lymphocytes.